drugset
drugset / Trial / NCT00552344

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

NCT00552344 ↗

Phase 3 Completed 403 enrolled UCB BIOSCIENCES, Inc. PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].

Timeline

Start
2008-05
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 400 mg Subcutaneous

Indications

Crohn disease